Despite increasing use of cell-based assays in high-throughput screening (HTS) and lead optimization, one challenge is the adequate supply of high-quality cells expressing the target of interest. To this end, cell lines stably expressing targets are often established, maintained, and scaled up by cell culture. These steps require large investments of time and resources. Moreover, significant variability invariably occurs in cell yield, viability, expression levels, and target activities. In particular, stable expression of targets such as transient receptor potential A1 (TRPA1) causes toxicity, cell line degeneration, and loss of functional activity. Therefore, in an effort to identify TRPA1 antagonists, the authors used large-scale transiently transfected (LSTT) cells, enabling rapid establishment of assays suitable for HTS. LSTT cells, which could-be stored frozen for a long period of time (e.g., at least 42 weeks), retained TRPA1 protein expression and could be easily revived to produce robust and consistent signals in calcium influx and electrophysiological assays. Using cells from a single transfection, a chemical library of 700,000 compounds was screened, and TRPA1 antagonists were identified. The use of LSTT circumvented issues associated with stable TRPA1 expression, increased flexibility and consistency, and greatly reduced labor and cost. This approach will also be applicable to other pharmaceutical targets. (Journal of Biomolecular Screening 2007:61-69) 
INTRODUCTION
I N RECENT YEARS, cell-based functional assays have been increasingly used in high-throughput screening (HTS) and lead optimization. 1, 2 Compared to cell-free assays using purified molecular targets, cell-based assays offer many advantages. For example, cell-based assays measure ligand-target interactions in a physiologically relevant environment. These assays can also distinguish mechanisms of action such as agonism, antagonism activities, and allosteric modulation. In addition, cell-based assays can be amended to poorly defined targets with no known ligands, such as orphan receptors. 1 The versatility and efficiency of cell-based functional assays are hindered by their demand for large quantities of high-quality live cells to support HTS campaign and follow-up studies, which are ongoing processes lasting from months to years. Typically, these assays require establishing cell lines, which stably express the target of interest, maintaining gene expression for a long period of time, regular passaging, and scaling up of the cells by cell culture. Each step can present daunting challenges. For example, establishing/characterizing/selecting stable clones with desired expression levels and activities, maintaining stable cell lines, and scaling up for HTS are extremely laborious, timeconsuming, and expensive. Intrinsic to living cells, significant variability occurs routinely in growth rate, yield, viability, and target activities. Moreover, the stable expression of certain targets can lead to cellular toxicity, which manifests as cell damage and decrease or loss of gene expression and target activity. 3 To overcome toxicities associated with constitutive expression of some genes, inducible expression systems have been attempted 4, 5 ; however, these systems still require generation of a stable cell line. Moreover, induction of gene expression on a large scale using these systems can be tedious, expensive, and inconsistent. In addition, "leaky" expression of some proteins, even at low levels, can lead to cell damage when cells are cultured for extended periods of time. Together, these factors significantly limit the practical use of inducible expression of targets for HTS campaigns.
Transient receptor potential A1 (TRPA1), also known as ANKTM1 and p120, belongs to the transient receptor potential (TRP) superfamily, which consists of a large group of cation channels that play critical roles in physiological processes, including vasorelaxation, fertility, cell growth, and sensory function. 6, 7 Like other family members, functional TRPA1 channels are formed by tetramerization of 4 subunits, each containing 6 transmembrane segments, a pore loop between the last 2 transmembrane segments, and intracellular N-and C-termini. Recently, several studies suggest that TRPA1 may play an important role in sensory function. TRPA1 is restrictively expressed in sensory neurons of dorsal root ganglia, trigeminal ganglia, and hair cells. [8] [9] [10] [11] [12] [13] In dorsal root ganglia and trigeminal ganglia, TRPA1 is specifically colocalized with pain markers, such as TRPV1, calcitonin gene-related peptide (CGRP), and bradykinin receptor. TRPA1 can be activated by pungent natural products, including allyl isothiocyanate (mustard oil, MO), cinnamaldehyde (cinnamon oil), eugenol (clove oil), methyl salicylate (wintergreen oil), gingerol (ginger), alicin (garlic), and acrolein (an irritant from tear gas and car exhaust fumes). 11,14-17 TRPA1 knockout mice display diminished response to environmental irritants and pronounced deficits in bradykinin-evoked pain hypersensitivity. 17 Intraplantar injection of cinnamaldehyde excited sensory neurons and induced nociceptive behavior in mice. 16 Moreover, antisense treatment could prevent and reverse cold hyperalgesia caused by inflammation and nerve injury in animal models. 13 However, due to the lack of selective small-molecule antagonists, the exact role of TRPA1 in sensation and its utility as a therapeutic target remain to be elucidated.
As a Ca 2+ -permeable channel, activation of TRPA1 mediates Ca 2+ influx into cells. It is possible that this property can be used to develop a Ca 2+ influx assay to identify TRPA1 antagonist modulators using a cell line stably expressing TRPA1. However, previous reports have shown that generating stable cell lines expressing TRPA1 is challenging. 9, 12 These cell lines were unhealthy and gradually lost TRPA1 expression and activity, possibly due to toxicity caused by a sustained Ca 2+ influx mediated by TRPA1 channel opening.
In this study, we have demonstrated the utility of large-scale transiently transfected (LSTT) HEK293-F cells for cell-based functional assays to identify TRPA1 antagonists. This strategy circumvents the need for developing stable cell lines and thus avoids the associated toxicity. This strategy enables rapid development of functional assays suitable for HTS. The LSTT cells expressing TRPA1 can be frozen, stored long term, and revived to produce robust and consistent signals in a Ca 2+ influx assay and by electrophysiological recordings. Using LSTT cells prepared from a single transfection, a library of > 700,000 compounds has been successfully screened, resulting in the identification of novel and potent TRPA1 antagonists.
MATERIALS AND METHODS

Molecular biology
TRPA1 full-length cDNA was amplified from human dorsal root ganglia total RNA (BD Bioscience Clontech, Palo Alto, CA) by using RT-PCR primers F1 (AATGGTACCGCGGCCGCAT-GAAGTGC AGCCTGAGGAAGATG) and A1 (ATACTCGAGC-CGCGGCTAAGGCTCAAGATGGTGTGTTT). The fragment was cloned into the pcDNA3.1/V5-His Topo vector (Invitrogen, Carlsbad, CA). Several mutations introduced by PCR error were corrected and the coding sequence confirmed by DNA sequencing.
Clonal cell line generation
Human embryonic kidney cells (HEK293) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO 2 at 37 °C. Cells were transfected with the pcDNA3.1/V5-His/TRPA1 plasmid using LipofectAMINE 2000 (Invitrogen) and subjected to antibiotic selection (1 mg/mL Geneticin) 48 h later. Single colonies (designated as P0) were selected 14 days posttransfection, amplified, and passaged once a week. The A8 clone was characterized by analyses of TRPA1 protein expression and channel function.
Large-scale transient transfection, freezing, and reviving
LSTT was performed using the FreeStyle™ 293 Expression System following protocols recommended by the manufacturer (Invitrogen). HEK293-F cells were grown in suspension in flasks (cell volume 30 mL to 1 L) or in a Wave Bioreactor (Wave Biotech, Somerset, NJ) (6 L). To support high density, suspension culture, and transfection, cells were cultured in FreeStyle™ 293 media, an optimized, serum-free formulation. 293fectin™ (Invitrogen) was used as transfection reagent. In a transfection of 3 × 10 7 cells (30 mL volume), 30 µg of plasmid DNA and 40 µL 293fectin™ were used. For a larger volume transfection, each reagent was scaled up proportionally. Two days posttransfection, cells were harvested by centrifugation (1000 g, 5 min) and resuspended to a density of 1.5 × 10 7 cells/mL in freezing medium (Freestyle media/10% serum/10% DMSO). Cells were transferred into cryovials in 2-mL aliquots, and these vials were placed in Nalgene Mr. Frosty slow-freeze devices (Sigma-Aldrich, St. Louis, MO) at -80 °C. As needed, vials were removed from -80 °C and quickly thawed in a 37 °C water bath. Cells were aseptically transferred into conical tubes containing FreeStyle media (10 mL/vial). After centrifugation at 1000 g for 3 to 5 min, the medium was removed by aspiration, and cells were resuspended in FreeStyle medium at desired densities (typically 1 × 10 6 cells/mL).
Antisera, immunoprecipitation, and Western blotting
Rabbit antisera (Ab1 and Ab2) were raised against 2 peptide sequences of human TRPA1: CSFQDRFKKEQMEARN (amino acids 1085-1110) and CLEMEILKQKYRLKDLT (amino acids 1040-1055 with an extra N-terminal cysteine). Briefly, peptides were coupled to maleimide-activated KLH via the N-terminal cysteine and injected into rabbits. Bleeds determined to have the highest titer for the purified peptides were affinity purified using the Pierce Ag/Ab immobilization kit with Sulfolink coupling gel.
Protein extracts were prepared from cells according to the protocol by Santa Cruz Biotechnology (Santa Cruz, CA). Briefly, 2.0 × 10 7 cells were collected and treated with 1.0 mL ice-cold RIPA buffer and fresh proteinase inhibitors. Cell lysates were centrifuged to remove debris, and protein was quantified. TRPA1 proteins were detected by Western blot analysis following immunoprecipitation. Briefly, after overnight incubation of 100 µg protein samples with Ab1 at 4 °C, immune complexes were precipitated with protein A agarose beads (Invitrogen) and washed extensively using RIPA buffer. After the final wash, pellets were resuspended in Laemmli sample buffer, and the proteins were resolved by SDS-PAGE (4%-12% gel) and transferred to a polyvinylidene fluoride (PVDF) membrane. The blot was developed with a 1:1000 dilution of Ab2 as primary antibody and horseradish peroxidase-linked donkey antirabbit IgG as secondary antibody (GE Healthcare, Piscataway, NJ). Immunoreactive proteins were detected on the blot with the ECL system (GE Healthcare).
Ca 2+ + influx assay
Ca 2+ influx assay was established in a 96-well format using the fluorometric imaging plate reader (FLIPR) and Ca 2+ assay kit (R8033; Molecular Devices, Sunnyvale, CA). A day prior to performing FLIPR experiments, LSTT cells or clonal cells were plated at a density of 100,000 cells/well (unless otherwise stated) in 96-well poly-D-lysine-coated clear-bottom black wall plates (BD Bioscience, Bedford, MA) and incubated overnight at 37 °C in a humidified atmosphere of 8% CO 2 . One vial of calcium dye was dissolved in 10 mL of Hanks' buffered salt solution (HBSS)/20 mM HEPES (assay buffer) and used as a 10× stock concentration as recommended by the manufacturer (Molecular Devices). After removing the media by aspiration, cells in each well were loaded with 100 µL 1 × Ca 2+ dye and incubated at room temperature for 1 to 2 h. To compensate for differences in cell confluency and dye loading, a signal test was performed before each FLIPR reading, and average fluorescence signals were adjusted to 15,000 relative fluorescence units (RFUs) by changing laser power and camera setting. Test compounds were prepared as 4× stock of desired concentration. A double addition protocol was used to evaluate agonist activity of mustard oil (MO; Sigma) and antagonist activity of ruthenium red (RR; Sigma). The protocol to determine activation by MO consists of a 10-sec baseline readout, followed by first addition of 50 µL assay buffer, a 3-min readout, a second addition of 50 µL MO (4× stock), and a 2.5 min readout. Fluorescence readings were taken every 1 sec. To determine antagonist activities, the first addition was 50 µL of RR (4× stock solutions), and the second addition was 50 µL of 120 µM MO. Differences between maximum and minimum signals before the second addition and end of FLIPR readings were used for data analysis. Concentration responses for MO and RR were analyzed using Origin 7 software (OriginLab Corp, Northampton, MA). Numerical values are reported as mean ± SEM (n = number of experiments). SEM is calculated by dividing the standard deviation by the square root of the sample size. Z factor, an indication of assay quality, was calculated using the following equation
HTS
HTS was performed in 384-well poly-D-lysine-coated, clear-bottom black plates (Greiner Bio-One, Longwood, FL), in which the cells were plated at a density of 25,000 cells/well using a 384-well Multidrop (Thermo Labsystems, Helsinki, Finland). The assay protocol was similar to the 96-well format, except for the following: 45-µL dye loading, 16 µL (5× stock) for the first addition, and 20 µL (4× stock) for the second addition. Compound screening was performed with 384-well mixed compound plates containing 10 compounds/well. Test compounds were formatted using a 10 × 10 orthogonal mixing strategy with each compound mixed with 9 other unique compounds per well on 2 separate microplates. 19 Such a strategy facilitates the identification of active compounds from mixtures. The testing concentration for each compound was 1 µM; the final DMSO concentration in each well was 0.25%, and at this concentration, DMSO did not affect TRPA1 function. Antagonists were identified based on their inhibition of 30 µM MO-induced calcium influx. After primary screening, hits were confirmed by retesting and IC 50 determination.
Electrophysiological recording
LSTT cells were also used for electrophysiological recordings. Specifically, 30 to 100 mL of HEK 293-F cells were transfected with hTRPA1 and green fluorescence protein (GFP) DNA in a 3:1 ratio. About 48 h after transfection, cells were harvested, frozen, and stored at -80 °C at 1 × 10 7 cells/mL. Two to 24 h prior to performing experiments, cells were revived and plated Utility of Large-Scale Transiently Transfected Cells for Cell-Based HTS on polyethylenimine-coated coverslips. Currents were recorded using an Axopatch 200B amplifier (Axon Instruments, Molecular Devices) and digitized at 3 kHz for acquisition. The chamber containing cells was continuously perfused with an extracellular recording solution (pH 7.4, 320 mOsm) consisting of (in mM) the following: 155 NaCl, 5 KCl, 1.6 MgCl 2 , 10 HEPES, 12 dextrose, and 5 EGTA. Patch electrodes were pulled from borosilicate glass and fire-polished to 2 to 6 MΩ tip resistance. The intracellular solution (pH 7.25, 280 mOsm) contained (in mM) the following: 122.5 K-aspartate, 20 KCl, 5 HEPES, 1 MgCl 2 , 10 EGTA, and 2 ATP-Mg. Cells with GFP-fluorescence were selected and voltage clamped at -60 mV. Drug applications were controlled through the ValveLink system (AutoMate Scientific, San Francisco, CA), which was connected to a common 360-mm polyimide tip positioned approximately 100 µm from the cell.
RESULTS AND DISCUSSION
Loss of TRPA1 protein expression in a clonal cell line
Human TRPA1 cDNA was amplified by PCR from dorsal root ganglia and cloned into pcDNA3.1/V5-His Topo vector for mammalian expression. HEK293 cells were transfected with human TRPA1 cDNA and selected using geneticin. After single colonies were isolated (designated as P0), cells were split once a week in the presence of geneticin. Despite frequent change of medium, all cell lines grew very slowly (doubling approximately once a week) and appeared unhealthy. These observations were consistent with previous reports that expression of TRPA1 was toxic to cells. 9, 12 To analyze TRPA1 protein expression in clonal cell line A8, polyclonal antibodies (Ab1 and Ab2) were raised in rabbits against synthetic peptides comprising amino acid residues 1085-1110 or 1040-1055 of human TRPA1, respectively. Total cellular protein was isolated from clonal A8 at passages 5 and 33 (P5 and P33) and untransfected HEK293 cells, and it was analyzed using Ab1 to immunoprecipitate TRPA1 and Ab2 for Western blot detection. Protein extracts from untransfected HEK293 cells did not yield any immunoreactive band. Lysates from A8 at passage 5 (A8-P5) showed a predominant immunoreactive band of ~127 kDa, which is the predicted size of TRPA1 protein, and a weaker band of ~150 kDa, possibly representing posttranslational modified protein (Fig. 1a) . In contrast, TRPA1 immunoreactive bands were not detected in lysates from clonal A8 at passage 33 (A8-P33), indicating a loss of TRPA1 expression during the 28 weeks in culture. These studies demonstrate that cell lines stably expressing TRPA1 could not be reliably sustained for assay development and HTS.
Retained TRPA1 protein expression in frozen cells from LSTT
To circumvent the problems encountered with generating stable cell lines, alternative strategies were explored. Transient expression of TRPA1 using the FreeStyle™ 293 Expression System was chosen for several reasons: the HEK293-F cell line has been adapted to high-density growth in suspension, which facilitates scale-up in bioreactors to generate large quantities of cells necessary for HTS. HEK293-F cells can also grow adherently on poly-D-lysine-coated plates as needed. In addition, the transfection reagent 293fectin™ enables high transfection efficiency with up to 80% cells transfected (data not shown). Moreover, after thawing from -80 °C storage, cells can be reliably revived with more than 90% viability. TRPA1 protein levels were monitored in cells from a single transfection, either fresh or after 35 weeks of storage at -80 °C. Two strong bands at 127 and 150 kDa existed in both samples, indicating that robust protein expression was maintained after 35 weeks of storage at -80 °C (Fig. 1b) .
A Ca 2+ + influx assay using frozen LSTT
Based on the robust TRPA1 expression, frozen/thawed LSTT cells expressing TRPA1 were used for assay development. Because TRPA1 channels are permeable to Ca 2+ , 9 a Ca 2+ influx assay using FLIPR instrument would be suitable for HTS. Mustard oil, one of the most potent and most characterized TRPA1 agonists, and ruthenium red, a nonselective antagonist, were used to activate or block TRPA1, respectively. 14 MO evoked concentration-dependent fluorescence increases in cells transfected with TRPA1 ( Fig. 2a) but not in untransfected cells or cells transfected with the vector pcDNA3.1 (data not shown). The concentration of MO required to induce a 50% of maximal fluorescence increase (EC 50 ) in TRPA1-expressing cells was 23.0 ± 3.8 µM (Fig. 2b) . The inhibitory effect of RR on MO-induced Ca 2+ influx was determined using 30 µM MO (the EC 60 concentration; Fig. 2c ). RR inhibited MO-induced fluorescence change in a concentration-dependent manner, with an IC 50 of 14.0 ± 2.1 µM (Fig. 2d) .
Comparison of fresh, frozen LSTT, and clonal cells
HTS and follow-up studies can last from months to years and require assays to be robust and consistent. Toward this purpose, the activities of a single batch of transfected cells, either fresh or stored frozen in -80 °C for different durations (1 week, 4 weeks, and 42 weeks), were monitored. Passage 10 of the clonal cell line A8 expressing TRPA1 was also evaluated. Similar conditions (e.g., cell plating density, incubation, dye loading, and basal signals) were used for all samples, and multiple parameters were determined. In response to 30 µM MO, the fluorescence signals were 30,917 ± 1829, 27,761 ± 1631, 25,579 ± 1061, and 25,184 ± 1329 RFUs for TRPA1-expressing fresh cells and cells frozen for 1 week, 4 weeks, and 42 weeks, respectively ( Table 1) . Signal-to-background ratios, as defined by signals induced by 30 µM MO versus buffer, were 15, 13.3, 11.8, and 12.0, respectively (Fig. 3b) . Although these data were derived from different experiments and comparisons of exact values should be cautioned, it was apparent that robust channel activities were retained in frozen LSTT cells.
The fluorescence signal and signal-to-background ratio obtained with the clonal cell line A8 at passage 10 were 16,136 ± 1123 RFUs and 9.8, respectively ( Table 1 ). The apparently smaller signal and lower signal-to-background ratio may result from a lower TRPA1 protein expression in the clonal cell line. At passage 33, the A8 cell line did not respond to MO, consistent with the complete loss of TRPA1 protein expression (data not shown).
To extend the characterization of these cells, their pharmacological responses to MO and RR were evaluated. The EC 50 values of MO were 21.3 ± 0.4, 23.0 ± 3.8, 15.1 ± 3.1, 16.9 ± 2.4, and 14.2 ± 3 µM for fresh LSTT cells; cells frozen for 1 week, 4 weeks, and 42 weeks; and the clonal cell line A8, respectively ( Table 1 ). The IC 50 values of RR inhibition were also quite similar (13.8 ± 0.9, 14 ± 2.1, 17.2 ± 3.5, 14.8 ± 2.5, and 11.2 ± 4.0 µM, respectively; Table 1 ). Taken together, these studies demonstrate that transiently transfected cells frozen for long periods retain robust signals and display pharmacological properties similar to fresh LSTT cells and the clonal cell line.
HTS using LSTT
Following optimization of the FLIPR-based Ca 2+ influx assay using TRPA1-expressing LSTT cells, a large batch of cells was prepared to screen the Abbott drug repository (> 700,000 compounds). Wave Bioreactor was used to grow and transfect 6 L of HEK293-F cells in a single batch. Fortyeight hours posttransfection, 1.05 × 10 10 cells, sufficient for plating more than one thousand 384-well plates, were harvested and frozen in small aliquots. This homogeneous population of cells would be expected to display minimal variability following thawing as needed for HTS. The fluorescence signals from individual wells in a 384-well plate, induced either by an addition of 30 µM MO or buffer, were determined (Fig. 3a) . The average signals were 30,911 ± 265 for MO and 2341 ± 81 RFUs for buffer, respectively (n = 48). The calculated signalto-background ratio was 13.2, Z′ factor was 0.75, and average percent coefficient of variation (%CV) was 5.9. TRPA1 antagonists were identified based on their ability to inhibit 30 µM
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MO-induced Ca 2+ influx. The scatter was minimal, and the antagonists were readily identifiable above the scatter (representative plot shown in Fig. 3b) . Compounds from the Abbott drug repository were screened as 10 compound mixtures. The hits were retested as single compounds, and IC 50 values were determined. Potent and novel TRPA1 antagonists were identified from the screen. Throughout the process of assay validation, screening, hit confirmation, and IC 50 determination, only a single batch of frozen cells was used; robust and consistent signals were maintained.
Intrinsic to clonal cell lines, cell passaging often results in changes in protein expression levels, target activity, and likely variation in compound potencies. To determine whether our screen could have been biased by using a single batch of frozen HSTT cells, selected hits-namely, compound A and compound B-were evaluated using 1 batch of frozen cells and 1 batch of fresh cells from a different transfection. For compound A, IC 50 was 80 ± 9.8 and 143 ± 12 nM obtained from using the fresh batch and frozen batch, respectively (Fig. 4a) . For compound B, IC 50 was 495 ± 46 and 524 ± 24 nM obtained from using the fresh batch and frozen batch, respectively (Fig. 4c) . The apparently similar potencies obtained from different transfection batches may represent their similar overall protein expression levels. Alternatively, this may be due to the fact that compound potency from each transfection is a cumulative readout from a pool of cells with different protein expression levels-hence a more consistent measurement than that obtained from a homogeneous population of clonal cells. In any case, these results support the notion that a high-quality screen has been achieved by using LSTT-expressiag TRPA1.
Electrophysiological characterization of HTS hits using frozen LSTT
To confirm the activity of hits from HTS, compound A and compound B were further evaluated by electrophysiological recording, which is considered the gold standard for assessing ion channel activity and pharmacology. Frozen LSTT cells were used for whole-cell patch clamp experiments. Using these cells, lasting, high-resistance seals (between patch pipette and cell membrane) and break-in could be routinely achieved to enable whole-cell recordings. Held at a holding potential of -60 mV, cells were stimulated with a 60-sec application of 100 µM MO, followed by a 20-sec coapplication of 100 µM MO with varying concentrations of compound A or B. Large inward currents were induced by MO and subsequently blocked by compounds A and B in a concentration-dependent manner (Fig. 4a,c) . To derive the concentration-effect relationship, the steady-state currents during antagonist application (usually the last 2 sec) were obtained, then normalized against the peak currents elicited by MO alone (Fig. 4b,d ). Using this method, the IC 50 value for block of TRPA1 currents was determined to be 98.5 ± 5.6 nM and 293 ± 47 nM for compound A and compound B, respectively. These values were largely comparable to those determined from Ca 2+ Samples include fresh large-scale transient transfection (LSTT) cells (fresh cells); same batch of cells frozen for 1 week, 4 weeks, and 42 weeks; and the clonal cell line A8 at passage 10 (A8-P10). Cells were seeded at a density of 100,000 cells/well except for A8-P10 (~120,000 cells/well). Potential variability in cell densities and dye loading were compensated by adjusting basal fluorescence signal to 15,000. Signals were fluorescence increase in responses to 30 µM mustard oil (MO). Signal-to-background ratios were determined by normalizing fluorescence signals elicited by 30 µM MO against signals induced by buffer addition. IC 50 for block of MO-induced Ca 2+ influx by ruthenium red (RR) was determined using 30 µM MO. TRPA1 = transient receptor potential A1. In electrophysiological experiments, the relationship was derived by normalizing steady-state currents during compound A coapplication (usually the last 2 sec) against the peak currents induced by 100 µM mustard oil (MO; as shown in Fig. 4b) .
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IC 50 values for compound A were 143 ± 12 (CI-Frozen), 80 ± 9.8 nM (CI-Fresh), and 98.5 ± 5.6 nM (EP) (n = 4-6). influx assays. Taken together, these studies confirm the antagonist activities of TRPA1 hits and demonstrate the utility of frozen transiently transfected cells for electrophysiological studies.
In summary, the present study describes the use of large-scale transiently transfected cells for cell-based HTS to identify novel TRPA1 antagonists. Compared with the use of stable cell lines, this strategy offers the following advantages: (1) it eliminates the need to establish, select, and maintain stable cell lines and thereby enables assays to be established within days instead of months.
(2) It circumvents problems associated with stable cell lines (e.g., toxicity and loss of protein expression). (3) Cells from a single preparation have consistent response signals. (4) A single preparation of a large quantity of cells can be transfected and frozen to support the entire HTS campaign and follow-up studies, leading to greatly reduced labor and cost. In our hands, 10 10 to 10 11 transfected cells can be routinely generated in a single batch. Besides TRPA1, this approach has been successfully applied to several other therapeutic targets in our hands. Similarly, it can also be adopted to other assay formats.
